Subscribe

Subscribe

Latest Content

Solar

Storage

Wind

Event Spotlight

BLOGS

DISTRIBUTECH+ RECAP: Energy Storage Utility Case Studies

Webcast

OPINION

RESOURCES

CLARION ENERGY MEDIA

POWER & ENERGY EVENT SERIES

Privacy Policy

Copyright © 2019 - 2021

Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Entrada Therapeutics Inc (NQ: TRDA )

17.22 +0.12 (+0.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 84,173
Open 17.50
Bid (Size) 16.52 (1)
Ask (Size) 17.95 (1)
Prev. Close 17.10
Today's Range 16.88 - 17.61
52wk Range 10.75 - 18.17
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Entrada Therapeutics Announces $100 Million Registered Direct Offering
– The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – 
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+13.51%
+13.51%
1 Month
+21.52%
+21.52%
3 Month
+39.55%
+39.55%
6 Month
+13.14%
+13.14%
1 Year
-0.35%
-0.35%

More News

Read More
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Recap: Entrada Therapeutics Q4 Earnings
Via Benzinga
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Entrada Therapeutics, Inc.
Via GlobeNewswire
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Entrada Therapeutics Reports First Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Insiders Buying America's Car-Mart And 2 Other Stocks
Via Benzinga
Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Promotes Nathan J. Dowden to President
From Entrada Therapeutics, Inc.
Via GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today?
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.